Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | ABL2 | P42684 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 8/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048714 | 1.00 | ABL1 (0.49) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL25048825 | 0.95 | CA2 (0.52) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL30941348 | 0.95 | CA2 (0.52) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL30941007 | 0.91 | CA2 (0.49) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL25046809 | 0.91 | CA2 (0.49) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL25048971 | 0.88 | CA2 (0.38) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL31618086 | 0.87 | METTL3 (0.59) | CA2METTL3 | |
| SCHEMBL25047810 | 0.87 | METTL3 (0.59) | CA2METTL3 | |
| SCHEMBL25047789 | 0.87 | METTL3 (0.58) | ABL1EGFRABL2CA2SRC | |
| SCHEMBL30940795 | 0.87 | METTL3 (0.58) | ABL1EGFRABL2CA2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | ABL1 186/4885EGFR 1687/4885ABL2 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.